SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
• Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
• Life expectancy (\> 1 year).
• New diagnosis of a renal tumor (within past 3 months).
• Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
• Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
• No definitive evidence of metastatic disease.
• Does not require urgent surgical treatment.
• Candidate for surgical, ablative, and surveillance approach.
• Willingness to obtain more information to aid decision-making.
• Understanding and willingness to provide consent.